Home
/

What is a HbA1c Blood Test?

REVIEWED BY
Bill Maish, MD
Clinical Content Consultant
Published
May 30, 2026
Last updated
May 30, 2026
Quick answer:

HbA1c measures the percentage of hemoglobin irreversibly glycated by glucose, reflecting average blood sugar over 2–3 months. Mid-5s are typical for non-diabetics, upper-5s to mid-6s indicate prediabetes, and ≥6.5% meets the diabetes threshold. Higher levels are associated with vascular complications including retinopathy, nephropathy, and cardiovascular events through advanced glycation end products.

Read more →
Table of contents

Hemoglobin coated by glucose

Hemoglobin A1c is hemoglobin with sugar attached. Inside red blood cells, glucose in the bloodstream slowly sticks to hemoglobin A, forming a stable sugar–hemoglobin adduct (non-enzymatic glycation of the beta-chain N-terminal valine, yielding a ketoamine called HbA1c). This happens continuously and irreversibly for as long as the red cell circulates. A blood test quantifies the share of total hemoglobin that has become HbA1c, so it is not about a momentary sugar reading but about how much hemoglobin has been exposed to glucose over time.

Because red blood cells live about three months, HbA1c captures your average glucose exposure over the past two to three months, with the most recent weeks weighing more. It smooths out day-to-day swings and reflects your longer-term glucose balance (chronic glycemia). In practical terms, it serves as the body's built-in logbook of sugar exposure, linking ongoing blood-glucose levels to the cumulative chemical changes they cause in proteins (glycation).

Why a three-month glucose average matters

Hemoglobin A1c is hemoglobin coated by glucose, averaging your blood sugar over the past two to three months. It captures the glucose exposure your organs receive and, in one number, signals risk to blood vessels, nerves, kidneys, eyes, and the heart.

Hemoglobin A1c (HbA1c) measures the share of hemoglobin that has glucose attached, integrating average blood glucose exposure over roughly three months. It is a window into how well your body matches glucose supply with insulin action. Because chronic glucose exposure modifies proteins and blood vessels, HbA1c relates to energy stability, vascular and nerve integrity, kidney and retinal health, cognition, immunity, and reproductive outcomes.

HbA1c integrates insulin secretion and sensitivity across liver, muscle, and fat, and the effects of diet, activity, stress, sleep, and medicines. It complements fasting glucose, glucose tolerance testing, fructosamine, and continuous glucose metrics. Healthier ranges align with stronger vessels, preserved organs, and lower lifetime risk of diabetes complications.

Reading your A1c across the diabetes thresholds

In most adults without diabetes, values sit in the mid‑5s; the upper‑5s to mid‑6s suggest prediabetes, and 6.5 or higher supports diabetes. Health risk generally falls as HbA1c moves into the lower‑normal range, but extremely low values can reflect trouble.

Low values usually reflect either genuinely low average glucose or faster red blood cell turnover that lowers the reading. True low glucose can manifest as shakiness and poor cognitive endurance when counter‑regulatory hormones surge. Apparent lows are common with conditions that shorten red cell lifespan (hemolysis, blood loss, late pregnancy, recent transfusion). In treated diabetes, very low values can signal frequent hypoglycemia, especially in older adults.

When HbA1c is unusually low, it may reflect chronic hypoglycemia—causing shakiness, sweating, palpitations, confusion, or seizures—because the brain depends on steady glucose. It can also read low when red blood cells turn over quickly, as with hemolysis, recent blood loss, or pregnancy, where shorter cell lifespan lowers the value.

Higher HbA1c signals sustained hyperglycemia. Excess glucose forms advanced glycation end products that stiffen arteries and thicken capillaries, leading to thirst, urination, fatigue, blurred vision, numbness, and infections. Over time this drives retinopathy, kidney disease, neuropathy, and cardiovascular events. In early pregnancy it raises fetal risk; in youth it predicts earlier complications.

High values usually reflect sustained hyperglycemia from insulin resistance or insulin deficiency. System‑level effects include endothelial dysfunction, oxidative stress, and impaired repair, increasing risks for retinopathy, kidney disease, neuropathy, cardiovascular events, infections, and cognitive decline. In pregnancy, higher early values indicate greater risk of adverse outcomes.

What can distort the A1c reading

Interpretation is influenced by age (values drift upward), iron deficiency (can falsely raise), hemolysis or recent blood loss/transfusion (can falsely lower), hemoglobin variants, kidney disease, and assay method. Glucocorticoids and some antipsychotics raise glucose. During mid‑to‑late pregnancy, HbA1c is less reliable; glucose testing is preferred.

The glycemic logbook, in one number

Being in range suggests stable glucose–insulin balance, flexible fuel use, and a lower "glycation burden" on tissues, supporting endothelial function, nerve signaling, and immune resilience. For cardiometabolic risk, within reference ranges often sits toward the lower end of the usual reference range, though individual targets vary with age and comorbidity.

FAQs

HbA1c measures the percentage of hemoglobin that is glycated, reflecting your average blood glucose over roughly the past 2–3 months.

Fasting glucose shows a single point in time, while HbA1c captures longer-term trends and is less affected by daily fluctuations from meals, stress, or illness.

No. HbA1c testing does not require fasting.

Persistently elevated blood glucose from diet, activity patterns, sleep, weight, or medication issues can raise HbA1c, increasing the likelihood of prediabetes or diabetes and related complications.

Frequent hypoglycemia, recent blood loss, hemolysis, certain hemoglobin variants, or advanced kidney disease can lower HbA1c independent of true glucose levels.

Superpower currently offers at-home blood testing in the following states: Alabama, Arizona, California, Colorado, Connecticut, Delaware, District of Columbia, Florida, Georgia, Idaho, Illinois, Indiana, Kansas, Maine, Maryland, Massachusetts, Michigan, Minnesota, Missouri, Montana, Nebraska, Nevada, New Hampshire, New Jersey, New Mexico, New York, North Carolina, Ohio, Oklahoma, Oregon, Pennsylvania, South Carolina, Tennessee, Texas, Utah, Vermont, Virginia, Washington, West Virginia, and Wisconsin.

We’re actively expanding nationwide, with new states being added regularly. If your state isn’t listed yet, stay tuned.

References

  1. Nathan, D. M., Kuenen, J., Borg, R., Zheng, H., Schoenfeld, D., & Heine, R. J. (2008). Translating the A1C assay into estimated average glucose values. Diabetes Care, 31(8), 1473-1478. https://doi.org/10.2337/dc08-0545
  2. American Diabetes Association Professional Practice Committee. (2024). 2. Diagnosis and classification of diabetes: Standards of Care in Diabetes-2024. Diabetes Care, 47(Suppl 1), S20-S42. https://doi.org/10.2337/dc24-S002
  3. Selvin, E., Steffes, M. W., Zhu, H., Matsushita, K., Wagenknecht, L., Pankow, J., Coresh, J., & Brancati, F. L. (2010). Glycated hemoglobin, diabetes, and cardiovascular risk in nondiabetic adults. The New England Journal of Medicine, 362(9), 800-811. https://doi.org/10.1056/NEJMoa0908359
  4. Selvin, E., Ning, Y., Steffes, M. W., Bash, L. D., Klein, R., Wong, T. Y., Astor, B. C., Sharrett, A. R., Brancati, F. L., & Coresh, J. (2011). Glycated hemoglobin and the risk of kidney disease and retinopathy in adults with and without diabetes. Diabetes, 60(1), 298-305. https://doi.org/10.2337/db10-1198
  5. American Diabetes Association Professional Practice Committee. (2024). 6. Glycemic goals and hypoglycemia: Standards of Care in Diabetes-2024. Diabetes Care, 47(Suppl 1), S111-S125. https://doi.org/10.2337/dc24-S006

Built by the world’s top doctors and scientists

Dr Anant Vinjamoori, MD

Chief Longevity Officer, Superpower

Board-certified longevity physician. Previously product leader at Virta Health & CMO at Modern Age. Featured in  WSJ, Forbes, and Fortune.

Learn more

Dr Leigh Erin Connealy, MD

Clinician & Founder of The Centre for New Medicine

Leads the largest integrative medical clinic in North America. A pioneer in integrative oncology.

Learn more

Dr Robert Lufkin

UCLA Medical Professor, NYT Bestselling Author

A leading voice on metabolic health and longevity as shown in The Today Show, USA Today and FOX.

Learn more

Dr Abe Malkin

Founder & Medical Director of Concierge MD

Leads a nationwide medical practice, and Drip Hydration, a mobile IV therapeutics company

Learn more
Membership slide 1
Membership slide 1
Membership slide 2
Membership slide 3
1 / 3

Your membership starts here

Annual 100+ biomarker panel

Data dashboard and digital twin

Upload past labs and connect wearables

Personalized health protocol

24/7 care team access

AI companion for all health questions

Marketplace with additional solutions

$199

/year*

Billed annually

HSA/ FSA eligible
Cancel anytime
Results in a week

* Pricing may vary for members in New York and New Jersey